Qiagen NV (QGEN) Company Overview

QGEN's strong performance in the fourth quarter of 2024 is supported by a robust portfolio.

Qiagen N.V. (NYSE:QGEN) will hold its Q4 2024 Earnings Conference Call on February 6, 2025, at 10:00 AM ET. The call will feature company representatives including John Gilardi, Thierry Bernard, and Roland Sackers. Participants from various financial institutions, such as Jefferies, Bank of America Securities, and Citi, will also be present.

While the revenue and earnings per share (EPS) for Qiagen (QGEN) provide insight into its performance for the quarter ending December 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.

Qiagen (QGEN) reported quarterly earnings of $0.61 per share, which is slightly below the Zacks Consensus Estimate of $0.62 per share. In comparison, the company earned $0.57 per share during the same period last year.

QGEN remains a focus for investors because of its strong growth in testing options and advantages from its strategic partnerships.

QIAGEN puts a lot of money into research and development to help its own growth, which includes adding new options to its main platforms.

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has revealed a new strategy to return around $300 million (up to EUR 281 million) to its shareholders. This will be done through a synthetic share repurchase that includes a direct capital repayment and a reverse stock split. This announcement follows a similar program in early 2024, which also returned about $300 million, totaling $600 million across both initiatives.

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has revealed a major enhancement to its QIAcuity Digital PCR (dPCR) system, allowing for more than double the number of targets to be analyzed at once from a single biological sample. This improvement addresses the design difficulties faced by existing quantitative multiplex PCR methods, making QIAcuity digital PCR suitable for various applications.

Qiagen (QGEN) has a strong track record of surprising with its earnings and currently has the right factors in place that suggest it may exceed expectations in its upcoming quarterly report.